"Write This Date Down..."

Ph.D. Trader Discovers U.S. Gov't "Glitch"
that Lets You Legally Pinpoint the Precise Dates
of Huge Stock Moves – WEEKS in advance.

Dear S&A Subscriber,

"Write this date down," said Dr. George Huang, early one Monday morning, about six months ago.

Then he handed me a notecard with a date and 4 letters scrawled across the front:

"Watch the markets closely that day. When you see it happen, let me know what you think."

Minutes after that unusual exchange, Dr. Huang left.

Sure enough, eight days later, something extraordinary happened:

That was only the beginning...

For the next six months, Pozen's stock soared... racing to $18.11 per share – an all-time high.

Had you bought shares when Dr. Huang first notified me that day in my office... you'd have seen a gain of 228%.

In about six months.

What caused Pozen's stock to rise so high... in such little time?

Better yet, how did Dr. Huang know the EXACT DAY Pozen would jump, days before it happened?

He told me soon after...

There's a Glitch in the System...

There was no earnings announcement.

No "insider" activity. No takeover bid.

No announcement from Pozen's management... or from any Wall Street analyst, either. Heck, the company's so small, none of the big Wall Street firms even cover it.

So... what caused this huge price move in such a short period of time? According to Dr. Huang, there's a "glitch" in one of the most important U.S. Federal Government Processes...

A gaping hole in the system that lets you legally know when the biggest trades of the year will be triggered -- WEEKS before they happen.

That's how Dr. Huang knew the precise date Pozen's share price would begin to move – long before it happened.

Of course, the folks in Washington have known about this vulnerability, but there's actually nothing they can do about it... except keep it as quiet as possible... and see if they can repair the damage.

Earlier this year... the US Congress secretly launched an investigation, hiring the Breckenridge Institute -- a third-party think tank in Colorado – to assess the situation.

Their report concluded:

"The introduction of a new system will be delayed up to 5 years."

In other words, there's nothing they can do to fix it anytime soon.

Simply stated, this glitch is imbedded deep within one of the biggest, most important agencies of the U.S. government. It will take years and years (plus billions of dollars) to alter.

In the meantime, we estimate you've got AT LEAST another 5 years to make the easiest, most extraordinary gains you've ever seen in the stock market.

In other words, with only a handful of trading dates throughout the year, you can safely make extraordinary gains... all thanks to one of the biggest agencies of the U.S. government.

How much money can you make?

Here's what we found out...

Consider the case of Advanced Magnetics (AMAG) – a NASDAQ-listed technology company, for example.
 
For years, AMAG's stock had been trading pretty flat. Most traders had written the stock off.

But then – in March 2005 – something extraordinary happened:

The stock took off... rising 471% in roughly one year... and 893% in 18 months.

Most investors never saw this rapid move coming.

But, incredibly, you could have known about this movement MONTHS before anyone else.

How?

Thanks to the "glitch" I mentioned earlier. What happens is this:

The Government releases a date, months in advance, which lets you know when certain stocks are set to quickly run-up in price.

In the case of Advanced Magnetics, the date was March 31, 2005.

Some in-the-know investors knew about this date more than 6 months in advance.

If you'd invested $5,000 in AMAG... you could have cashed out in 18 months with $44,650 in your pocket.

Advanced Magnetics and Pozen are just two of the examples Dr. Huang showed me from a database he's spent the past year constructing.

He's documented 69 similar instances from the past eight years.

In every single one of these 69 cases, you could have known when the stock would begin to jump... MONTHS before it happened:

Others have returned even more money...

Like Actelion (ATLN), which shot up 985%.

And Biomarin (BMRN), whose shares jumped 16% on Jan. 29, 2003. By March 2006, you could've made as much as 911%.

Crunching the overall numbers, here's what Dr. Huang found...

Crush the U.S. Stock Market by 600%

Overall, Dr. Huang documented and analyzed 69 separate "Federal glitch" companies from June 2001 through December 2007...

On average, these companies – all 69 of them – on a percentage basis – crushed the NASDAQ by about 600% over an 18-month period.

Even better...

Dr. Huang spent most of last year analyzing these 69 "glitch" events... and he developed a 4-pronged trading strategy that isolates only those stocks that rise the fastest and highest in value.  

In fact, Huang's strategy successfully isolated the 16 biggest winners out of that original pool of 69 companies:

16 trades.

16 winners.

100% effective.

And the best part is... you can know EXACTLY when these trades are going to be triggered.

Here's what I mean...  

And in the meantime... collect gains 5-10 times higher than ordinary investors.

You could sail to the Caymans for 3-4 weeks. Start your first novel. Work on your golf game. The main thing is, to get away from the computer and get out to enjoy the real world.

Sounds nice, doesn't it?

Well, it's not hypothetical. It's very realistic. Very attainable – no matter how much or how little you know about trading.

What I find most extraordinary about this situation is that in the months to come, you can know EXACTLY which days are likely to be your most profitable ones in the stock market.

For example, here are the upcoming trading dates you should mark on your calendar:

I don't know what you have planned for these days right now. But whatever you've got going on, I suggest you rearrange your schedule, because you've got the chance to make a heck of a lot of money, no matter what's happening in the U.S. economy or stock market a whole.

I thought I'd seen it all in 12 years as a trader, analyst, and active investor. But what Dr. Huang described shocked even me. It's easily the most remarkable stock market phenomenon I've ever seen.

Dr. George Huang knows about this situation from first-hand experience.

He's spent the better part of the past decade working in academic institutions, as a contractor with the U.S. government, and with private firms. In each position, he worked closely with this Federal Agency, and learned more about how the system works.

Along the way, he figured out an extraordinary way to make money.

I have to warn you:

When you read the full explanation, it will probably sound as if it may be illegal.

But I assure you, we've done an incredible amount of legwork on this situation. Dr. Huang has criss-crossed the country 5 times in the past year to check it out. And we've had our in-house counsel review the entire process with a fine-tooth comb.

So how does this government glitch work, exactly?

Let me show you an example. It's actually the opportunity Dr. Huang first used to make a lot of money thanks to this gift from the Federal government...

The Best Day to See a 1,641% Return

Have you ever heard of Celgene Corporation (NASDAQ: CELG)?

It's one of the best performing U.S. stocks this decade.

In April 2001 – long before the U.S. financial community had ever heard of the company – Dr. Huang picked up Celgene at $4.25 per share for his own portfolio.

He knew at the time what the rest of the world would later learn...

That Celgene's medical technologies were legitimate... their business model was sound... and one of the products under development was potentially worth $300-$400 million and would soon send this company hurtling from obscurity and into the public eye.

In 3 years, Dr. Huang's investment in Celgene rose 230%.

But then, something amazing happened...

After quadrupling in value over 2 years, beginning Oct. 22, 2004, shares of Celgene really took off.

In five years, the stock shot up 1,641%. That's the same as turning every $5,000 into $82,050.

What happened here?

Let me show you...

And sent to certain publicly traded U.S. companies like Celgene...

This 6-story office building houses the Food and Drug Administration – commonly known as the FDA.

Every American knows about the FDA... to some extent.

They give final approval on nearly all new medical treatments in the U.S..

Of course, they give final approval of prescription drugs such as Lipitor and Celebrex. But that's just one small part of what the FDA does.

They regulate American food: Corn from the Midwest. Pork imported from China.

Commercial breakthroughs in nanotechnology.

Even cosmetics.

And herein lies our opportunity....

The "glitch" I've alluded to throughout this letter – and the greatest opportunity for you to make money over the next 5+ years...

You just write the date down... and watch the money roll in.

Here's how it works...
 

What's the "Glitch?"

In short, the FDA has an incredible backlog of products, treatments, and new drugs to review.

They're understaffed. And, like most bloated bureaucracies, they are incredibly inefficient.

But unlike most government red tape, the FDA's bureaucratic mess can actually work in your favor as an investor. In short, it can help you make incredibly large profits, safely... in a relatively short period of time.

Here's what I mean...

You see, during the review process of a new drug or medical treatment, the FDA will sometimes quietly send out a particular type of letter (known in the business as an Approvable Letter) to the company that's having its new treatment tested.

What most people don't know is that this letter has little to do with whether or not the new treatment will gain final FDA approval... but it has an immediate and dramatic effect on the share price.

This letter that goes out near the end of the review process. And if you know how to read these letters properly, they can make you a heck of a lot of money, very quickly.

Even more amazing:

The FDA will tell you exactly when these letters will be sent. So you can actually mark the dates on your calendar, if you wish. (As you'll see in a few moments, we've prepared an internal trading calendar with every single one of these dates. We'll give you access to a printable copy)

And if you buy shares in these companies SHORTLY AFTER the Approvable Letter arrives, you stand to make a fortune over the ensuing months.

It happens again and again in this industry.

The FDA sends a one-page letter toward the end of its Review Process...

And in-the-know investors get rich:

Dr. Huang's database contains dozens of examples much like these.

So... how do you know which companies are the best to buy... and when?

Let me explain...

What the Feds Don't Want You to Know:

If this all sounds a bit unusual, I'm not the least bit surprised.

At first, I was very skeptical. After all, I'd spent many years as a professional trader before joining S&A.

And I'd never heard of "APPROVABLE LETTERS," or how easily one could make a fortune trading on them.

So I insisted that Dr. Huang walk me through dozens of examples... and show me exactly how it works, every step of the way.

And that's exactly what he's done over the past few months.

Dr. Huang showed me the results of his 8-year back-testing study – and the trading strategy he developed.

It is, hands down, one of the most incredible trading breakthroughs I've ever witnessed.

That's why I've sent this letter to you, specifically.

Dr. Huang and his team have created a trading research service based on this new breakthrough:

Called the S&A FDA REPORT, it tracks these APPROVABLE LETTER situations... and alerts you to upcoming trades, using Dr. Huang's proprietary 4-pronged strategy (you'll see this in action in just a few moments.)

Before I tell you what to expect from the plays Dr. Huang has lined up (he's been tracking 4 set to be triggered within the next 30 days)...

I should answer a question you've probably been asking:

If you really can make a fortune trading on these APPROVABLE LETTERS... then why don't more people know about it?

For starters, very few analysts or traders anywhere in America have the expertise to understand this phenomenon...

Let alone to deconstruct it... to interpret the data on these letters properly... and to create a trading strategy that's not only very low-risk... but also 100% successful.

You see, the particular stocks this government "glitch" affects (predominately those in the healthcare sector) follow their own set of rules.

Their shares move in ways that defy typical financial analysis.

Consider a company like Advanced Magnetics (AMAG), which I mentioned earlier.

In 2005, most traders down in the pits wouldn't have wiped the sweat off their brow with AMAG's balance sheet.

But if they'd known that AMAG's radically innovative nanotechnology would soon revolutionize diagnostic medicine in the U.S.... they could have cashed in on the 893% profits AMAG's stock quickly generated.

Perhaps you can see why APPROVABLE LETTERS remain such a secret. Very few folks are qualified to trade on them.

That brings me to another big reason you've likely never heard of this market situation until now...

Right now I have Dr. Huang's 2008 trading calendar in front of me.

It lists every single company scheduled to receive one of these letters from the FDA – all the way through November 2008 – 7 whole months from now.

51 potential trades.

Could every one of these trades rise in value? Sure, remember, according to Dr. Huang's study, if you simply bought every stock that received an Approvable letter, you could have made an average of 19% gains.

But Dr. Huang's only going to recommend a fraction of these opportunities to trade on. Once he applies his 4-pronged trading technique to this database....

The list gets much, much smaller.

Only the most fertile ones remain. How does Dr. Huang filter out the chaffe?

Get in...Get Paid... Get Out.

Dr. Huang focuses on companies with market capitalizations smaller than $500 million.

In other words, the big blue chip companies automatically get cut.... And only the smallest stocks remain.

Why?

In short, because it's almost impossible to double your money or better in a short period of time, on a really big stock.

Consider: On July 18, 2006, drug giant Johnson & Johnson received an approvable from the FDA. And the stock gained about $15,120,000,000 in value. But for a large company like J&J, that equates to only an 8% move.

Not bad... but barely a blip when you compare it to a small company like NPS Inc (NPSP), which received an approvable letter around roughly the same time as J&J.

Shares of NPS surged 168% in roughly the same time.

That's why Dr. Huang focuses his attention on  the smallest companies in the market, with the potential for the biggest moves.

You see, Dr. Huang looks for the biggest possible returns over a 12-18 month period. He wants you to get in, get paid, and get out pretty quickly. The FDA REPORT is, after all, a trading research service.

So how much money can you expect to make with these FDA trades... and when is the next upcoming opportunity?

I'll explain everything in a minute. But first, I wanted to tell you about one more aspect of this situation.

You see... this opportunity with Approvable Letters gets even better.

I knew you probably wouldn't believe if I told you this earlier...

But now that you know how this situation works... and have seen the proof for yourself...

Well, let me show you what I mean...

The 8-Hour Stock Boost

I haven't yet told you how taking advantage of this government "glitch" can give your portfolio a huge one-day boost.

I'm talking about last-minute, double-digit surges to these tiny "glitch" stocks... in addition to the kinds of gains I've been telling you to expect.

These huge one-day jumps typically appear several weeks after a company receives an Approvable Letter. And the returns are a great little bonus.

For example:

MedImmune (MEDI): received an approvable letter on July 18, 2006... nearly doubling in just a few months. Most of the money you could have made came suddenly, in the matter of hours:

What sends these Approvable Letter stocks soaring?

I won't spoil the secret here. You'll have immediate access to the full details on the Approvable Letter from Dr. Huang's recently published FDA Report trading Primer.

Every subscriber to our new FDA REPORT will receive access of this primer.

This is the very first thing you need to read if you want to take advantage of these trades. Inside, Dr. Huang explains in greater detail everything I've touched upon so far:

• The full story behind FDA's systemic "GLITCH"
  
  
• How it indicates MAJOR stock movements – MONTHS before they actually happen
  
  
• Why it's perfectly legal – and ethical – to trade on this market anomaly
  
  
• The Secrets Behind Dr. Huang's 4-Pronged Strategy for Trading on this Phenomenon

I'll stop right here. Very simply, the information it contains represents the most essential conclusions and secrets Dr. Huang spent more than a year uncovering...

As a new FDA REPORT subscriber, you can claim your copy today – in the next 30-90 minutes. Right on your computer.

Read it as soon as you can. Dr. Huang does all the legwork. Once you're ready for a taste, all you have to do is write the APPROVABLE dates down... and trade when he sends you an alert.

But read over this primer today. You'll want to be up to speed ASAP. There are 4 potential trades set to be triggered in the next 30 days.

On the first day, shares of this tiny company will spike. Somewhere between 20-30%. Soon after, if Dr. Huang's timing indicator falls into place, he'll issue a "BUY" alert to you and to your fellow FDA REPORT members.

How much money might you make from this trade?

According to Dr. Huang:

"Depending on the outcome in the weeks after the company receives the FDA letter... this could be the most lucrative trade of the year."

How do you make this trade?

If Dr. Huang issues a "Buy," he'll send you an e-mail right away. Then, simply call up your broker, or log-on to your online brokerage account. Buy shares of this CA-based company, just as you would any other time you've invested in a stock.

But please remember: Don't deviate from Dr. Huang's recommendation. If you choose to make this trade, follow his guidance exactly.

You'll get the full details on this play as soon as you become an FDA Report subscriber. But before you rush out to buy shares of this company – or invest in any of these recommended trades, for that matter – there's something vitally important you need to know...

After crunching 8 years worth of Approvable Letter data... Dr. Huang discovered a pattern in the returns that surprised him.

So he re-ran the analysis.

Same result.

The numbers don't lie:

How much more?

6-7-times more, on average.

So... how long after a company receives one of these letters should you wait before loading up on shares?

Well, I'm sure you'll understand — this information is reserved for subscribers only.

But don't worry.

Like I said, it's hands-off and easy for you to capitalize on. I won't say much more here... but just know Dr. Huang developed a timing indicator that lets him know EXACTLY when to buy shares in these government "glitch" opportunities. (I'll get to this in just a moment.)

You'll find everything you might want to know about Dr. Huang's strategy in the FDA REPORT primer.

Along with your FDA REPORT primer, you'll receive a copy of Dr. Huang's trading calendar...

It's a master list of every letter scheduled for release this year.

The companies set to receive them...

And the precise dates for each event.

Access to Dr. Huang's
Master Trading List...

When you become an FDA REPORT subscriber, you'll receive a calendar of potential trades – the dates and ticker symbols of companies scheduled to receive approvable letters – all the way through November 2008.

51 companies in total.

Will Dr. Huang recommend trading on every single one of these events?

On average, Dr. Huang's timing indicator falls into place 23% of the time.

In other words, expect the FDA Report to be very selective in the positions we take.

That's the luxury of an airtight and extremely precise trading strategy.

And to preserve Dr. Huang's carefully calibrated trading strategy – if you intend to trade for maximum profits - it's important that you not deviate from the specific instructions in the alerts you'll receive as an FDA REPORT member.

This list is for your own personal use. We'll assume by accepting your charter membership you're also giving us your word this list will not fall into the hands of anyone else.

We take this project seriously... and ask that you do the same.

That being said, if you're amped up and ready to start collecting the easiest money you'll ever see...

Then let's get to it...

To access your copy of Dr. Huang's master calendar, just follow the link at the end of this letter.

You'll receive access to it right away, along with your FDA Report Trading Primer.

Claim your membership today to make sure you receive it.

I believe you'll soon agree with me that there's simply no better way to make extremely large gains... with little risk.

The Federal Government takes care of just about everything for you:

1) They will tell you, with an APPROVABLE LETTER, which stock to buy and when to buy it.

2) Dr. George Huang will tell you exactly which trades offer the biggest rewards. Plus, Dr. Huang's timing indicator tells you EXACTLY when you should buy after a company receives one of these little-know letters.

To get started, here's what you do:

That's it.

Sounds ridiculously simple, I know. That's exactly why we're so excited at Stansberry & Associates about launching the FDA REPORT.

A one-year subscription to the FDA REPORT cost $2,400.

I realize this isn't cheap. As I mentioned, Dr. Huang focuses on companies with market capitalizations smaller than $500 million and if too many people were too get involved in these situations, no one would benefit as a result.

Dr. Huang wants you to get in, get paid, and get out pretty quickly. The FDA REPORT is, after all, a trading research service.

Since you're a loyal S&A Reader, we want you to be happy. We know this service will improve your net worth... and hopefully deepen our relationship. I have no doubt you can make money from Dr. Huang's trade recommendations – no matter WHAT the market might be doing at the time.

You'll have 90 DAYS to decide whether Dr. Huang's research is right for you. If for whatever reason you want to cancel your subscription in the first ninety days, just let us know. We'll give you a full refund. After all, the success of our business as an independent financial publisher rests entirely on you.

If you like our work and think our investing strategy is right for you, then you stick with us and S&A continues growing as a business.

So sign up today – claim your charter membership for the limited time we're offering it. And take the next 3 months to follow Dr. Huang's trades.

Here's what you'll receive as an FDA REPORT subscriber:

• FDA REPORT TRADING PRIMER: Remember, this special, members-only report represents your TRADING BIBLE. Read it right away, before you review anything else. You'll learn the full details on this unique situation... and the secrets behind Dr. Huang's proprietary 4-pronged strategy for optimizing potential returns on these trades, including his timing indicator, which lets you know the PRECISE time to pull the trigger.
  
  
• FDA REPORT CALENDAR: This members-only special report lists EVERY SINGLE letter scheduled to be sent out by the FDA – all the way through November 2008. That's 51 events in total. Nothing quite like this exists anywhere else in the financial world. So again, we'll take you on your word that this information will be for you and for you alone.
  
  
• FDA REPORT Trading Alerts – Once a company receives an approvable letter, Dr. Huang will monitor the situation closely, waiting for his timing indicator to fall into place. When it does, he'll send you an email with specific trading instructions - when and how to buy at the right price, how long to hold, and how much money you should expect to make. I hope you'll decide to join us.

To take advantage of this unique opportunity, Subscribe Now

Sincerely,

Brian Hunt
Editor in Chief, S&A Research

Subscribe Now